Work

Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.7028

Authors: Anjali S. Advani, Daniel J. DeAngelo, David I. Marks, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan Mary O'Brien, Elias Jabbour, Akil Abid Merchant, Tao Wang, Erik Vandendries, Alexander Neuhof, Hagop M. Kantarjian

Institutions: Cleveland Clinic, Dana-Farber Cancer Institute, University Hospital Münster, Stanford Medicine, Stanford University, University of Chicago, Goethe University Frankfurt, University of California, Irvine, The University of Texas MD Anderson Cancer Center, University of Southern California, Pfizer (United States), Pfizer (Germany)

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890840454

Cites:

Cited by: 2

Related to: 10